Digestive and Liver Disease最新文献_第3页

Unveiling the role of HIV in HCC recurrence after liver transplantation: An Italian perspective. 揭示HIV在肝移植后HCC复发中的作用：意大利的观点。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-13 DOI: 10.1016/j.dld.2025.05.010

Chiara Becchetti, Maria Francesca Donato, Andrea Lombardi

引用次数: 0

Author's reply: Comment on "Sarcopenia in patients receiving TIPS is independently associated with increased risk of complications and mortality". 作者回复：评论“接受TIPS的患者的肌肉减少症与并发症和死亡率的风险增加独立相关”。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-12 DOI: 10.1016/j.dld.2025.05.027

Emma Vanderschueren, Wim Laleman

引用次数: 0

Comment on "Claudin-2: A marker for a better evaluation of histological mucosal healing in inflammatory bowel diseases". “Claudin-2：更好地评价炎症性肠病组织学黏膜愈合的标志物”评论。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-10 DOI: 10.1016/j.dld.2025.05.014

Muhammad Hasan, Muhammad Hammad Chola

引用次数: 0

Endoscopic palliation of multiple gastric metastases from melanoma by device-assisted endoscopic full-thickness resection. 通过器械辅助的内镜全层切除来缓解多发性胃转移性黑色素瘤。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-10 DOI: 10.1016/j.dld.2025.05.021

F De Vincentis, L Carloni, D Castronovo, A Mussetto

引用次数: 0

Endoscopic assessment and scoring in pediatric inflammatory bowel disease: A consensus from SIGENP. 儿童炎症性肠病的内镜评估和评分：SIGENP的共识。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-09 DOI: 10.1016/j.dld.2025.05.020

Matteo Bramuzzo, Sara Renzo, Flavio Labriola, Serena Arrigo, Sara Lega, Erasmo Miele, Lorenzo Norsa, Salvatore Oliva, Claudio Romano, Paola De Angelis

{"title":"Endoscopic assessment and scoring in pediatric inflammatory bowel disease: A consensus from SIGENP.","authors":"Matteo Bramuzzo, Sara Renzo, Flavio Labriola, Serena Arrigo, Sara Lega, Erasmo Miele, Lorenzo Norsa, Salvatore Oliva, Claudio Romano, Paola De Angelis","doi":"10.1016/j.dld.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.dld.2025.05.020","url":null,"abstract":"Mucosal healing is the main treatment goal in the management of pediatric inflammatory bowel diseases (IBD), and accurate endoscopic assessment is essential for evaluating disease severity, monitoring progression, and assessing therapeutic responses. However, the wide variability of mucosal lesions, combined with the lack of standardized guidelines and limited training opportunities, complicates the scoring process and contributes to discrepancies in scoring accuracy. To address these issues, a panel of Italian pediatric endoscopists with expertise in IBD, convened by the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (SIGENP), developed practical recommendations for assessing endoscopic lesions and applying endoscopic scoring systems in pediatric IBD. These guidelines, based on a review of current literature and expert consensus, aim to improve the consistency, reliability, and accuracy of endoscopic evaluations in children with IBD. By providing clear recommendations, the guidelines seek to enhance the reliability of scoring systems, ultimately supporting more effective disease management and treatment outcomes for pediatric patients.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn's disease: results from the multicentre retrospective real-life study MUST. ustekinumab的即时药物优化对克罗恩病中期目标的影响：来自多中心回顾性现实研究MUST的结果

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-07 DOI: 10.1016/j.dld.2025.05.024

M Hupé, A Abdelmoula, T Chateau, S Pestour, X Roblin, C Gay, G Boschetti, S Nancey, N Mathieu

{"title":"Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn's disease: results from the multicentre retrospective real-life study MUST.","authors":"M Hupé, A Abdelmoula, T Chateau, S Pestour, X Roblin, C Gay, G Boschetti, S Nancey, N Mathieu","doi":"10.1016/j.dld.2025.05.024","DOIUrl":"https://doi.org/10.1016/j.dld.2025.05.024","url":null,"abstract":"Background and aim: Whether immediate drug dose intensification is a valuable option to optimize ustekinumab efficacy in Crohn's disease (CD) remains unknown. We compared the one-year efficacy of immediate optimisation of ustekinumab 90 mg to 4-weekly with standard 8-weekly dosing in bio-exposed CD patients.Methods: All consecutive CD patients starting ustekinumab between 2019 and 2020 were included in this multicentre retrospective study, either with immediate drug intensification (MUST group), or standard dosing (STD group). Primary endpoint was combined clinical and biomarkers remission at 52 weeks. A multivariate analysis was led to adjust for main prognostic factors, and a sensitivity analysis was added using a propensity score adjustment.Results: 203 adult patients were included, 59 in the MUST group and 144 in the STD group. No significant difference in baseline characteristics was found between groups. At week 52, 21 (35.6 %) patients were in combined remission in the MUST group, as compared to 26 (19.7 %) in the STD group (p = 0.028). This remained significant in multivariate analysis (OR = 2.84 [1.30-6.31]) and after propensity score adjustment (OR = 1.32 [1.10-1.57]).Conclusion: This study found that immediate escalation of ustekinumab therapy to 4-weekly dosing could achieve higher remission rates at one year than 8-weekly dosing in refractory CD.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe enterocolitis associated with phosphatidylinositol 3-kinase delta inhibitors: A multicentre cohort study. 与磷脂酰肌醇3-激酶δ抑制剂相关的严重小肠结肠炎：一项多中心队列研究

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-07 DOI: 10.1016/j.dld.2025.05.005

Marc Howaizi, Vered Abitbol, Mathieu Uzzan, Nassim Hammoudi, Jean-Marie Michot, Antoine Meyer, Franck Carbonnel, Aurelien Amiot

{"title":"Severe enterocolitis associated with phosphatidylinositol 3-kinase delta inhibitors: A multicentre cohort study.","authors":"Marc Howaizi, Vered Abitbol, Mathieu Uzzan, Nassim Hammoudi, Jean-Marie Michot, Antoine Meyer, Franck Carbonnel, Aurelien Amiot","doi":"10.1016/j.dld.2025.05.005","DOIUrl":"https://doi.org/10.1016/j.dld.2025.05.005","url":null,"abstract":"Introduction: Phosphatidylinositol 3-kinase-δ (PI3Kδ) inhibitors have been approved for treatment of patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas and may lead to enterocolitis.Patients and methods: This is a multicenter, retrospective cohort study. Consecutive patients treated with PI3Kδ inhibitors who developed severe enterocolitis.Results: Between 2014 and 2023, 31 out of 133 (23 %) patients exposed to PI3Kδ inhibitors had severe enterocolitis. Among them, 71 % required hospitalization, 64 % experienced weight loss and 39 % of patients had acute kidney injury. Endoscopic lesions were mild in 15/19 patients while four patients had shallow ulcers. Histopathological examination of colonic biopsies was abnormal in all cases. The most common lesions were neutrophilic cryptitis, crypt abscesses, crypt epithelial cell apoptosis and crypt architectural abnormalities. PI3Kδ inhibitors were discontinued in 24 cases (77 %). At day 30, clinical remission was achieved in 0/7 patients who continued PI3Kδ-inhibitor and in all patients who discontinued PI3Kδ-inhibitor (p < 0.001) with no benefit of adding prednisone or budesonide to treatment discontinuation. Relapse of diarrhea occurred in four out of seven (57 %) patients who resumed half-dosed PI3Kδ inhibitor.Conclusion: Severe enterocolitis associated with PI3Kδ inhibitors is frequent and respond to drug withholding. Steroids do not seem to provide additional benefits. Rechallenge is often accompanied by a relapse.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Environmental enteropathy and inflammatory bowel disease are not mutually exclusive. 环境性肠病和炎症性肠病并不相互排斥。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-07 DOI: 10.1016/j.dld.2025.05.001

Phoebe Hodges, Mubbunu Malambo, Wamundila Kawana, Ellen Besa, Monica Mweetwa, Violet Kayamba, Victor Mudenda, Nicholas M Croft, Paul Kelly

{"title":"Environmental enteropathy and inflammatory bowel disease are not mutually exclusive.","authors":"Phoebe Hodges, Mubbunu Malambo, Wamundila Kawana, Ellen Besa, Monica Mweetwa, Violet Kayamba, Victor Mudenda, Nicholas M Croft, Paul Kelly","doi":"10.1016/j.dld.2025.05.001","DOIUrl":"https://doi.org/10.1016/j.dld.2025.05.001","url":null,"abstract":"Background: Environmental enteropathy (EE) is an asymptomatic lesion of the small intestine, likely an adaptive response to environmental noxa, including enteropathogens, leading to recurrent intestinal injury, mucosal inflammation, and microbial translocation. Inflammatory bowel disease (IBD) is increasing in incidence in newly industrialised countries. Given that EE is seen in individuals living in insanitary environments in low-income countries (LICs) and IBD has traditionally been viewed as a disease of developed countries, we hypothesised that these two conditions would not co-exist.Aims: To investigate whether EE is seen in individuals with IBD living in a low-income country in sub-Saharan Africa.Methods: Enteropathy was assessed in adult Zambians with IBD and controls from high and low socio-economic status (SES) groups with duodenal biopsies and biomarkers of intestinal and systemic inflammation. Enteropathogen carriage rates between the groups were compared.Results: 28 cases and 59 controls (38 high SES and 21 low SES) were included. Histological features of EE were present in all cases and controls, with median villus height to crypt depth ratio <2 in all groups. Enteropathogen carriage was lower in cases (median of 1 pathogen per case to 2 per control).Conclusion: The co-existence of IBD and EE within the same individuals may prove to be a confounding factor when assessing patients presenting with symptoms suggestive of IBD in this setting and could be interpreted as evidence that improved environmental hygiene does not play a significant role in the emergence of IBD.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author's reply: Claudin-2 immunochemistry in IBD. 作者回复：Claudin-2在IBD中的免疫化学。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-07 DOI: 10.1016/j.dld.2025.05.022

Vincenzo Villanacci, Rachele Del Sordo, Gabrio Bassotti

引用次数: 0

Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial. 转移性结直肠癌个体化贝伐单抗剂量：一项III期随机试验的统计学考虑

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-06-06 DOI: 10.1016/j.dld.2025.05.009

Yue Lv, Jiaying Yu, Wei Ye

引用次数: 0